How to Read a GLP-2/Tirz Certificate of Analysis (COA)
A Certificate of Analysis is only useful if you know which number on it matters for the compound in front of you. For GLP-2/Tirz, the informative checks are not the same as for a generic short peptide.
Overview
Confirm the weight near 4813.5. As with GLP-3/RT, ask for a clumping measurement alongside purity — standard testing can miss clusters. For a 39-part chain, also look at the separation trace for incomplete versions that sit very close to the main peak.
What GLP-2/Tirz actually is
GLP-2/Tirz is an engineered molecule acting on two receptors in the gut-hormone system involved in blood-sugar regulation. It carries a design detail that is very widely misreported: it was built on a GIP backbone and then modified to also engage GLP-1, whereas most compounds in its class went the other way round.
Supplied for laboratory research use only — not for human or animal use.
Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.
Technical detail below
Assays that are informative for GLP-2/Tirz
What to check on the COA
Confirm the mass near 4813.5 Da. As with GLP-3/RT, aggregate content is the check that RP-HPLC purity alone will not give you. For a 39-residue synthesis, also review the chromatogram for closely eluting deletion sequences.
Deletion and truncation sequences, des-acyl species missing the fatty-acid chain.
Verify a Popular Peptides batch
Every batch is third-party tested by HPLC and LC-MS with a published Certificate of Analysis (≥99% purity). Enter a lot number to pull the COA for the exact vial in front of you.
What GLP-2/Tirz is studied for
Simultaneous GIP and GLP-1 receptor activity from a GIP-derived backbone.
Core metabolic research endpoints for the incretin class.
A well-characterised GLP-1 pathway effect studied in metabolic models.
Whether GIP agonism or antagonism is the productive direction remains an active research debate.
Summarizes published preclinical literature — see the selected references below. Provided for research reference only; not a claim of efficacy or a description of human use.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. GLP-2/Tirz Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
- Browse current GLP-2/Tirz literature on PubMed
References describe in-vitro and preclinical research and are listed for reference only — not evidence of efficacy and not a description of human use.
More GLP-2/Tirz reference
Lyophilized and reconstituted storage conditions, plus the practical working window.
Diluent selection, dissolution behaviour, and the calculator preset for this compound.
Which solvents work, why, and what abnormal dissolution behaviour indicates.
The specific chemical routes by which this molecule breaks down, and how to limit each.
Compound-specific bench practices, and the errors most often made with this molecule.
What to inspect on arrival, and which conditions actually warrant rejecting a vial.
Questions specific to this compound — structure, chemistry, and common misconceptions.
Purity & COA reference for other compounds
Reviewed for research-use compliance by Kobi Williams, Founder — Popular Peptides Canada. Last reviewed 22 July 2026.
GLP-2/Tirz is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.